Genmab A/S (NASDAQ:GMAB – Get Free Report) is set to announce its earnings results before the market opens on Thursday, May 2nd. Analysts expect the company to announce earnings of $0.16 per share for the quarter. Genmab A/S has set its FY 2024 guidance at EPS.
Genmab A/S (NASDAQ:GMAB – Get Free Report) last issued its quarterly earnings data on Wednesday, February 14th. The company reported $0.36 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.34 by $0.02. The firm had revenue of $675.29 million during the quarter, compared to the consensus estimate of $678.14 million. Genmab A/S had a return on equity of 18.06% and a net margin of 26.50%. On average, analysts expect Genmab A/S to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.
Genmab A/S Price Performance
NASDAQ GMAB opened at $28.47 on Thursday. The company has a market cap of $18.83 billion, a P/E ratio of 29.66, a P/E/G ratio of 2.08 and a beta of 0.99. The stock has a 50-day moving average of $29.46 and a two-hundred day moving average of $30.14. Genmab A/S has a 1-year low of $26.32 and a 1-year high of $42.72.
Analysts Set New Price Targets
Check Out Our Latest Report on GMAB
Genmab A/S Company Profile
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.
Read More
- Five stocks we like better than Genmab A/S
- Compound Interest and Why It Matters When Investing
- High-Yield Texas Instruments Could Hit New Highs Soon
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- Pagaya Technologies: An AI Fintech That Insiders Are Buying
- Why Invest in High-Yield Dividend Stocks?
- Higher Oil Prices Could Give NextEra’s Stock Earnings a Boost
Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.